CIK 0001557746 · Non-accelerated filer<br>Smaller reporting company
Aclaris Therapeutics, Inc.
Sign in to watch- Ticker
- ACRS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 460571712
- Phone
- 484-324-7933
- Business address
- 701 LEE ROAD, SUITE 103, WAYNE, PA, 19087
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-02-02 | Walker Neal Director | Sale | −3,121 | $16.88 | $53K | 1,175,963 |
| 2023-02-02 | Walker Neal Director | Sale | −200 | $17.54 | $4K | 1,175,763 |
| 2023-02-01 | Walker Neal Director | Sale | −25,000 | $16.75 | $419K | 1,180,763 |
| 2023-02-01 | Monahan Joseph Chief Scientific Officer | Grant or award · Employee Stock Option (Right to Buy) | +105,000 | 105,000 | ||
| 2023-02-01 | Monahan Joseph Chief Scientific Officer | Grant or award · Restricted Stock Units | +30,000 | 30,000 | ||
| 2023-02-01 | Manion Douglas J. Pres and CEO | Grant or award · Employee Stock Option (Right to Buy) | +378,000 | 378,000 | ||
| 2023-02-01 | Manion Douglas J. Pres and CEO | Grant or award · Restricted Stock Units | +108,000 | 108,000 | ||
| 2023-02-01 | Loerop James Chief Business Officer | Option exercise | +11,250 | 11,250 | ||
| 2023-02-01 | Loerop James Chief Business Officer | Grant or award · Employee Stock Option (Right to Buy) | +105,000 | 105,000 | ||
| 2023-02-01 | Loerop James Chief Business Officer | Grant or award · Restricted Stock Units | +30,000 | 30,000 | ||
| 2023-02-01 | Loerop James Chief Business Officer | Option exercise · Restricted Stock Units | −11,250 | 33,750 | ||
| 2023-02-01 | Cawkwell Gail Chief Medical Officer | Grant or award · Employee Stock Option (Right to Buy) | +105,000 | 105,000 | ||
| 2023-02-01 | Cawkwell Gail Chief Medical Officer | Grant or award · Restricted Stock Units | +30,000 | 30,000 | ||
| 2023-02-01 | Balthaser Kevin Chief Financial Officer | Grant or award · Employee Stock Option (Right to Buy) | +105,000 | 105,000 | ||
| 2023-02-01 | Balthaser Kevin Chief Financial Officer | Grant or award · Restricted Stock Units | +30,000 | 30,000 | ||
| 2023-01-04 | Walker Neal Director | Sale | −15,000 | $14.89 | $223K | 1,205,763 |
| 2023-01-03 | Walker Neal Director | Sale | −23,382 | $15.19 | $355K | 1,222,381 |
| 2023-01-03 | Walker Neal Director | Sale | −1,618 | $16.16 | $26K | 1,220,763 |
| 2022-12-15 | Monahan Joseph Chief Scientific Officer | Sale | −5,000 | $15.88 | $79K | 96,386 |
| 2022-11-14 | SCHIFF ANDREW N Director | Sale | −1,371 | $17.08 | $23K | 434,455 |
Page 22 of 34 · 680 trades